Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $163.4 million.

  • Arrowhead Pharmaceuticals' Other Working Capital Changes rose 1175185.45% to $163.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $174.7 million, marking a year-over-year increase of 600601.76%. This contributed to the annual value of $9.9 million for FY2025, which is 34370.54% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Other Working Capital Changes is $163.4 million, which was up 1175185.45% from -$13.0 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $163.4 million during Q4 2025, with a 5-year trough of -$76.2 million in Q1 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Other Working Capital Changes value was -$1.5 million (recorded in 2024), while the average stood at -$1.3 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Other Working Capital Changes plummeted by 12328990.62% in 2023 and then soared by 1175185.45% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Other Working Capital Changes stood at -$27.4 million in 2021, then grew by 16.25% to -$23.0 million in 2022, then soared by 116.52% to $3.8 million in 2023, then plummeted by 136.93% to -$1.4 million in 2024, then surged by 11751.85% to $163.4 million in 2025.
  • Its Other Working Capital Changes stands at $163.4 million for Q4 2025, versus -$13.0 million for Q3 2025 and -$20.3 million for Q2 2025.